ArticleDiagnostic pathology2012
CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma.
Article in Diagnostic pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 80 citations in OpenAlex.
- Trial
- Topological importance of CD8Annals of hematology · 2025Article
- Immunophenotypic Profile of Adult Glioblastoma IDH-Wildtype Microenvironment: A Cohort Study.Cancers · 2024Article
- Recycled melanoma-secreted melanosomes regulate tumor-associated macrophage diversification.The EMBO journal · 2024Article
- Mesenchymal stem cells-macrophages crosstalk and myeloid malignancy.Frontiers in immunology · 2024Review
- An updated portrait of monocyte-macrophages in classical Hodgkin lymphoma.Frontiers in oncology · 2023Review
- The Effect of the Tumor Microenvironment on Lymphoid Neoplasms Derived from B Cells.Diagnostics (Basel, Switzerland) · 2022Review
- High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.BMC cancer · 2022Article
- Hodgkin Lymphoma: A Special Microenvironment.Journal of clinical medicine · 2021Review
- Relationship of Tumor-Associated Macrophage Population Detected by CD68 PG-M1, CD68 KP1, and CD163 with Latent EBV Infection and Prognosis in Classical Hodgkin Lymphoma.Turk patoloji dergisi · 2021Article
- Metabolic reprograming of tumor-associated macrophages.Annals of translational medicine · 2020Review
- Tumor-associated macrophages in classical Hodgkin lymphoma: hormetic relationship to outcome.Scientific reports · 2020Article
- Clinico-pathological significance of immunohistochemically marked tumor-associated macrophage in classic Hodgkin lymphoma.Journal of the Egyptian National Cancer Institute · 2020Article
- Plasmablastic Lymphomas: Characterization of Tumor Microenvironment Using CD163 and PD-1 Immunohistochemistry.Annals of clinical and laboratory science · 2020Article
- CD163 is a predictive biomarker for prognosis of classical Hodgkin's lymphoma in Saudi patients.Molecular and clinical oncology · 2019Article
- Identification of a novel monocytic phenotype in Classic Hodgkin Lymphoma tumor microenvironment.PloS one · 2019Article
- The Role of Monocyte/Macrophage and CXCR3 in Differentiation between Recurrent Hepatitis C and Acute Cellular Rejection Postliver Transplantation.Journal of immunology research · 2018Article
- The Role of Macrophage/B-Cell Interactions in the Pathophysiology of B-Cell Lymphomas.Frontiers in oncology · 2018Review
- Spatial Mapping of Myeloid Cells and Macrophages by Multiplexed Tissue Staining.Frontiers in immunology · 2018Article
- Tumacrophage: macrophages transformed into tumor stem-like cells by virulent genetic material from tumor cells.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Classical Hodgkin lymphoma (CHL) is a B-cell lymphoproliferative disorder with a relatively good prognosis. A small but significant percentage of patients, however, will respond poorly to therapy. A recent gene expression profiling study has identified a macrophage signature which has been correlated with primary treatment failure, and immunohistochemical tissue microarray for CD68 was shown to reflect the gene signature as a potentially clinically useful marker to predict adverse prognosis.We examined 44 cases of CHL, mostly nodular sclerosis subtype, in which the immunohistochemical stains for the histiocytic markers CD68 and CD163 were performed. The staining intensity was graded for each stain (< 5, 5-25, and > 25 percent of cells positive in the Hodgkin cell (HC) rich nodules) and background staining characteristics were recorded.CD163 staining was lower than CD68 in HC rich nodules, with lower background staining (p 0.03). There was no significant difference between either CD68 or CD163 and disease recurrence in a subset (N = 41) of cases.In conclusion, we demonstrate that CD163 staining is lower than CD68, with less non-specific staining of background inflammatory cells and Hodgkin cells, therefore is a better marker for tumor associated macrophages. However, we did not identify a correlation between staining for CD68 or CD163 and recurrence of disease. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here:http://www.diagnosticpathology.diagnomx.eu/vs/1460518258831620.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.